Form 4: RA Capital Reduces VOR Biopharma Stake

RA Capital Management and its affiliated funds sold 117,050 shares of Vor Biopharma Inc. common stock in late October 2025 through pre-planned transactions.

Summary

• RA Capital Management, L.P., along with its affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P.) and managing members (Peter Kolchinsky and Rajeev M. Shah), reported sales of Vor Biopharma Inc. common stock.
• A total of 117,050 shares of common stock were sold across multiple transactions on October 20 and October 21, 2025.
• The sales were executed at weighted average prices ranging from $28.11 to $30.12 per share.
• Following these transactions, RA Capital Healthcare Fund, L.P. beneficially owns 1,401,226 shares, while RA Capital Nexus Fund, L.P. no longer holds any shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales.
• Peter Kolchinsky and Rajeev Shah, both directors and 10% owners, are among the reporting persons, along with the funds they manage.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a 10% owner and director group. While the sales were pre-planned under a 10b5-1 plan, the reduction in beneficial ownership by a key institutional investor is generally perceived unfavorably by the market.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating pre-scheduled transactions rather than reactive selling based on new, undisclosed information.

Negatives

• Significant insider selling by a 10% owner and director group can be perceived as a negative signal regarding future company prospects or valuation.
• The RA Capital Nexus Fund, L.P. fully divested its holdings in Vor Biopharma Inc. common stock.

Risks

• The filing itself does not detail specific company risks; however, insider selling by a major shareholder and director could be interpreted by the market as a perceived risk by the selling party.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Vor Biopharma Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of insider transactions and does not provide information to analyze broader industry trends or competitor activities.

Related Party Transactions

• The reported sales involve RA Capital Management, L.P., its affiliated funds, and its managing members (Peter Kolchinsky and Rajeev M. Shah), who also serve as directors and 10% owners of Vor Biopharma Inc. These transactions are considered related party dealings due to the reporting persons' significant influence and board representation.

Stakeholder Impact

• Shareholders may interpret the insider selling as a lack of confidence from a major investor, potentially leading to negative sentiment and downward pressure on the stock price.
• The reduction in ownership by a significant institutional investor could alter the shareholder base and influence future corporate governance dynamics.

Key Dates

Recommendation

While the insider selling by RA Capital Management and its affiliates is a negative signal, the transactions were pre-planned under a Rule 10b5-1(c) plan, which mitigates the immediate concern of reactive selling. The group still retains a substantial beneficial ownership of over 1.4 million shares. Investors should hold, but monitor future filings and company performance closely for further indications of insider sentiment or operational changes.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Trading, Stock Sale, Form 4, Beneficial Ownership, Director Transaction, 10b5-1 Plan